Market News

Senstar Tech (NASDAQ:SNT) reported quarterly earnings of $0.07 per share. This is a 75 percent increase over earnings of $0.04 per share from the same...

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and ...

Raymond James analyst Ryan Deschner downgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowers the price target from $28...

Uber Technologies remains a compelling buy, with a $100 target price and >43% upside driven by robust free cash flow. Read more on UBER stock here.

Debt reduction and margin gains lifted results despite weaker golf rounds.

International sales now make up 47% of Monster's total revenue.

Industrial and data center demand pushed sales higher amid tight capacity.

Sales productivity hit a record as the company logged its first Act 4 revenue.

Corporate growth and debt paydown drove another quarter of gains.

Merck patent setbacks in the U.S. cloud an otherwise strong quarter for royalties.

Management flagged tougher comparisons ahead after a strong quarter for Cloud and AI adoption.

Canopy Growth (NASDAQ:CGC) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. Th...

Nvidia CEO Huang faces congressional scrutiny over suspected Chinese intelligence ties, chip diversion concerns and AI security safeguards.

HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.

FANG, TRNS, WF, PTON and TBCH have been added to the Zacks Rank #1 (Strong Buy) List on November 6, 2026.

Strategic review and Outdoor growth define a mixed third quarter.

Cash flow surged and debt fell, but management flagged softer margins ahead.

Ginkgo cut its quarterly loss 44% as it pivots to autonomous labs.